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Pancytopenia represents a unique challenge for primary care doctors and its etiological causes encompass various 
specialties, including hematology and rheumatology. Despite the existence of effective tests such as bone marrow 
biopsy and immunoassays to rule out the potential causes of pancytopenia, it is often difficult to pinpoint the exact 
diagnosis. In this case report, we have described such a ‘gray zone’ patient, who presented with pancytopenia, neu-
tropenia, and splenomegaly, and was being treated for fungal pneumonia before being transferred to Severance 
Hospital (department of family medicine). As the patient had a 10-year history of multiple, long-term hospital ad-
missions that were having a severely debilitating impact on the quality of life, we performed a partial splenic embo-
lization as a potential cure for the symptoms. Although this induced acute blood count recovery, it failed to prevent 
eventual mortality from septic shock.
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Pancytopenia is a condition that can prove to be a diagnostic challenge 
for primary care physicians. It can be caused by a wide variety of etiol-
ogies, namely bone marrow failure, marrow infiltrating lesions, auto-
immune disorders, infections, and nutritional deficiencies,1) and is 
usually managed by a hematologist or a rheumatologist, depending on 
the etiology. As the potential causes are directly related to various 
anomalies of the bone marrow, a bone marrow biopsy is one of the 
most critical investigations for managing a patient with pancytope-
nia.1,2) In Korea, malignancy is a common diagnosis from bone mar-
row biopsies, but a substantial percentage of patients have unspecific 
findings.2) Recent terminology describes this condition as idiopathic 
cytopenia of undetermined significance (ICUS).3) However, little is re-
ported regarding the epidemiology and clinical characteristics of this 
condition. Once autoimmune causes are also ruled out, the affected 
patients are in what is described as a clinical ‘gray zone’ where neither 
hematologic nor rheumatologic management alone can completely 
provide patients with comprehensive medical care. This adversely af-
fects their quality of life as well as clinical status. This case report de-
scribes the clinical history and management of a 69-year-old man with 
longstanding pancytopenia along with splenomegaly and neutrope-
nia, in the department of family medicine at a Korean tertiary hospital. 
Accordingly, we have explored the role of family medicine in the man-
agement of such ‘gray zone’ patients.
CASE REPORT
A 69-year-old man was referred to the department of family medicine 
at Severance Hospital for chronic weakness and recurrent admissions 
for untreated and undiagnosed longstanding pancytopenia, which 
had persisted for the last 10 years. The patient had severe splenomega-
ly and was being treated for fungal pneumonia (aspergilloma and 
Pneumocystis jirovecii pneumonia) before the referral. There was past 
medical history of right thyroidectomy (for thyroid cancer), posterior 
right coronary artery stenting (due to chronic stable angina pectoris), 
and paroxysmal atrial fibrillation. The repeated admissions were se-
verely crippling the patient’s quality of life. The current admission was 
for exacerbation of fungal pneumonia. Upon initial evaluation, the pa-
tient was afebrile, with body temperature of 36.5°C and blood pressure 
of 99/66 mm Hg. Heart rate was 77 beats per minute and respiratory 
rate was 20 per minute. The patient showed poor nutritional status, 
weighing 48.7 kg with a height of 169 cm (body mass index [BMI], 
17.05 kg/m2). The patient appeared cachectic and exhausted by pro-
longed admission.
 Initial laboratory studies showed pancytopenia with neutropenia 
(absolute neutrophil count [ANC], 150/μL; reference, >1,500/μL), hy-
ponatremia (131 mmol/L), and increased prothrombin time (12.9 sec-
onds) and partial thromboplastin time (41.1 seconds). C-reactive pro-
tein (40.3 mg/L) and erythrocyte sedimentation rate (59 mm/h) were 
also elevated. Additional routine laboratory test results are shown in 
Table 1. Screening for infection yielded no evidence of cytomegalovi-
rus infection, or other causes of atypical pneumonia. Cultures of the 
blood and sputum were negative, but urine culture yielded 1,000 colo-
ny-forming units/mL of Gram-positive cocci. On chest X-ray, multiple 
nodular consolidations were observed in the left upper lung, and a 
chest computed tomography (CT) scan further demonstrated multiple 
nodular consolidations in the right upper lobe with a small amount of 
left pleural effusion and pericardial effusion. No enlarged lymph nodes 
were identified, and the enlarged spleen measured 21.4 cm.
 Initial medications upon admission included aspirin, nicorandil, 
trimetazidine, bisoprolol, and levothyroxine for the treatment of the 
underlying conditions. Moreover, total parenteral nutrition was initiat-
ed to compensate for the patient’s nutritional deficit. Antibiotic thera-
py was commenced with trimethoprim/sulfamethoxazole, meropen-
em, and amphotericin B, as was used in the previous clinic. However, 
as the chest CT scan indicated minimal possibility of active Pneumo-
cystis pneumonia, and polymerase chain reaction for Pneumocystis 
jirovecii was also negative, amphotericin B was administered as the 
sole antifungal agent. Additionally, prophylactic antibacterial agents 
were reduced to cefepime, since the fever had subsided by the time 
the patient was transferred to Severance Hospital.
 Consultations from the departments of hematology, rheumatology, 
and infection were sought, and the differential diagnosis focused on 
the evaluation of splenomegaly, pancytopenia, and neutropenia. Pe-
ripheral blood smear revealed normochromic, normocytic anemia 
with a reticulocyte percentage of 0.65%. Screening test results for iron 
deficiency anemia indicated anemia of chronic disease, with elevated 
Table 1. Initial laboratory investigations performed on day 1 of admission (7/16/2019)
Test Results
Complete blood count Total WBC 540/μL (neutrophil 28%, lymphocyte 51.6%, monocyte 13.1%), hemoglobin 9.9 g/dL, platelet count 37×103/μL
Electrolytes Na 131 mmol/L, K 4.1 mmol/L, Cl 101 mmol/L, Ca 7.5 mg/dL, P 2.5 mg/dL
Liver function test Albumin 2.7 g/dL, alkaline phosphatase 147 IU/L, aspartate aminotransferase 30 IU/L, alanine aminotransferase 19 IU/L,  
gamma-glutamyltransferase 75 IU/L, bilirubin 0.8 mg/dL
Renal function test Blood urea nitrogen 14.8 mg/dL, creatinine 0.8 mg/dL
Urine analysis with microscopy Color: yellow, turbidity: clear, pH 7.0, protein: trace, red blood cells 0–2/HPF, WBC 0–2/HPF
Blood coagulation test Prothrombin time 12.9 s, activated partial thromboplastin time 41.1 s
Cardiac markers CK 34 IU/L, CK-muscle/brain 1.5 ng/mL, troponin-T 26 pg/mL, N-terminal prohormone of brain natriuretic peptide 1,284 pg/mL
Inflammatory markers C-reactive protein 40.3 mg/L, erythrocyte sedimentation rate 59 mm/h
WBC, white blood cells; HPF, high power field; CK, creatine kinase.
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ferritin (3,308.5 ng/mL) and low transferrin (98 mg/dL) along with 
normal serum iron level (79 μg/dL). In addition, there was no defi-
ciency of B12 and folate. Bone marrow biopsy revealed an average cel-
lularity of 60%, with no signs of bone marrow failure. The detailed re-
sults can be found in Table 2, and follow-up results for complete blood 
counts are listed in Table 3.
 Prior bone marrow biopsies had similarly failed to indicate a diag-
nosis, which made primary hematologic disease unlikely. Subse-
quently, investigations were performed for potential autoimmune 
causes, and these yielded positive anti-nuclear antibodies (ANA) with 
a titer of 320:1 and rheumatoid factor (RF) levels of 23 IU/mL. After a 
rheumatology consultation, further studies were performed revealing 
weakly-positive anti-DNA (19 IU/mL) and anti-cardiolipin immuno-
globulin M antibodies (11 MPL-U/mL). Anti-beta2-glycoprotein 1 an-
tibodies and lupus anticoagulant were both negative. Serum C3 was 
low (36.7 mg/dL), but C4 was normal (11.98 mg/dL). Furthermore, 
when the patient was evaluated for lupoid manifestations, an oral ul-
cer was found, but no other autoimmune features were seen, includ-
ing skin rash, arthritis, muscular weakness, uveitis, and Reynaud phe-
nomenon. Cystatin C was elevated (1.53 mg/L), and cystatin C-based 
estimated glomerular filtration rate (GFR) was 42.6 mL/min/1.73 m2. 
Although the creatinine level was normal (0.82 mg/dL), its diagnostic 
value was limited due to the low BMI of the patient. Considering the 
ongoing infection, the presence of renal failure was deemed indeter-
minate. Follow-up investigations showed equivocal levels of anti-DNA 
antibodies (10 IU/mL), therefore, the elevation of rheumatologic anti-
bodies was tentatively considered to be a by-product of infection upon 
further consultation.
 With other possible causes of pancytopenia ruled out, splenomegaly 
itself was suspected to be the cause of the pancytopenia. During the 
hospitalization, the pancytopenia progressively worsened, and by day 
11 of hospitalization, total white cell count reached 540/μL (neutrophil 
35.9%), hemoglobin 6.8 g/dL, and platelet count 57×103/μL. Moreover, 
onset of sepsis was suspected, with body temperature of 37.0°C, blood 
pressure of 86/52 mm Hg, and pulse rate of 84. After an infusion of 1.5 
L of fluid did not raise the blood pressure to baseline levels, filtered red 
blood cells were transfused, along with norepinephrine at a rate of 4 
mL/h. Given the patient’s indeterminate diagnosis and deteriorating 
general condition, splenectomy was considered as a curative treat-
ment option. However, considering the poor condition of the patient, 
surgical splenectomy was deemed as hazardous, and partial splenic 
embolization was considered as an alternative. During the course of 
hospitalization, numerous consultations were sought but due to the 
failure to establish a definite diagnosis, no specific department could 
agree to actively transfer the patient from our department. Partial 
splenic embolization was undertaken on day 17 of hospitalization, us-
ing iodixanol as a contrast agent, and ultrasound guidance for arterial 
access. Vascular access point was right common femoral artery, and 
after performing celiac angiography and splenic angiography, the low-
er portion (70%) of the spleen was embolized with gelfoam. Intra-pro-
cedural images are shown in Figure 1.
 The day after embolization, there were no serious complications 
and a general increase in blood counts was observed; white blood cell 
count rose to 820/μL, hemoglobin to 10.0 g/dL, and platelet count was 
45×103/μL. However, 2 days after the procedure, at 11 PM, the patient’s 
temperature rose to 38.5°C, followed by a rapid drop to 35.7°C in an 
Table 2. Screening investigations for hematologic disease
Test Date Results
Peripheral blood smear 7/17/2019 Normocytic normochromic anemia with anisocytosis; marked leukopenia; moderate thrombocytopenia
Iron deficiency evaluation 7/17/2019 Serum iron 79 μg/dL; total iron binding capacity 140 μg/dL; transferrin saturation 56%; ferritin 3,308.5 ng/mL; 
transferrin 98 mg/dL
Vitamin B12 & folate 7/17/2019 Vitamin B12 12,334 pg/mL; folate 8.98 ng/mL
Bone marrow biopsy 7/19/2019 Average cellularity 60%; normal myeloid/erythroid ratio; full maturation of erythroid and myeloid series; shift to left of 
myeloid series; adequate number of megakaryocytes; interstitial hemosiderin deposition and infiltration of numerous 
CD3+ T-cells and some CD138+ plasma cells, favor reactive; reticulin stain: grade 0 myelofibrosis (normal)
Table 3. Complete blood count and C-reactive protein on follow-up (7/16/2019–8/4/2019)
Date White blood cell count (103/μL) Hemoglobin (g/dL) Platelet count (103/μL) C-reactive protein (mg/L)
Reference (Range, 4.0–10.8) (Range, 13.0–17.4) (Range, 150.0–400.0) (Range, 0–8)
7/16 0.54 9.9 37 40.3
7/19 0.52 9.5 22 29.0
7/20 0.51 8.5 23 32.4
7/21 0.68 9.5 23 40.9
7/22 0.75 9.1 35 53.7
7/23 0.67 8 41 79.0
7/25 0.73 8.4 56 79.7
7/26 0.59 8.4 54 -
7/27 0.73 8.6 52 66.1
7/28 0.75 7.9 62 -
Jaehee Cho, et al. • A Patient with Neutropenia and Splenomegaly
https://doi.org/10.4082/kjfm.19.0130
www.kjfm.or.kr  253
hour accompanied by a decrease in blood pressure to 84/56 mm Hg 
and a pulse rate increase to 148 per minute. Septic shock was suspect-
ed; therefore, norepinephrine and fluids were infused and CT scans of 
the chest and abdomen were undertaken. Notably, there was no pul-
monary embolism or bowel perforation, and the abdominal CT image 
is shown in Figure 2. After 2 hours of resuscitation, increased rales 
were heard in the lungs, and oxygen saturation began to fall, eventual-
ly reaching 55%. Consequently, mechanical ventilation was initiated. 
However, given the grim prognosis, the legal guardians of the patient 
refused to give consent for admission to the intensive care unit for 
closer monitoring and treatment. The patient began to show signs of 
cardiac arrest at 5 AM, when cardiopulmonary resuscitation (CPR) 
was commenced. Nevertheless, spontaneous circulation could not be 
established and the patient died 60 minutes into CPR at 6 AM.
 Written informed consent for publication of this image was ob-
tained from the patient.
DISCUSSION
This case report describes a case of pancytopenia with splenomegaly 
in an elderly man. Specifically, pancytopenia and accompanying neu-
tropenia (initial ANC 88/μL) were the major issues, and a history of 
multiple, long-term admissions was severely jeopardizing the patient’s 
quality of life. No definite diagnosis could be made in spite of a range 
of rheumatologic and hematologic evaluations conducted in our hos-
pital and in previous hospitals. All investigations yielded similar results 
and did not meet any specific diagnostic criteria. This suggested a di-
agnostic ‘gray zone,’ where the patient’s general condition clearly indi-
cated severe pathologic changes, but no definite diagnosis could be 
assigned; thus, this case could be described as a case of ICUS. ICUS is 
defined as an unexplained persistent cytopenia which fails to be diag-
nosed as myelodysplastic syndrome (MDS) by the accepted criteria. 
Cytopenia must be substantial and observed for at least 6 months, and 
upon diagnosis, a thorough hematologic follow-up, similar to that in 
low-risk MDS is warranted due to its possible progression to MDS or 
another myeloid disorder over time.3)
 The differential diagnoses we considered were aplastic anemia, leu-
kemia, myelofibrosis, and MDS among hematologic causes, and sys-
temic lupus erythematosus (SLE) among autoimmune causes. With 
respect to hematologic causes, multiple bone marrow biopsies per-
formed at the current and previous hospitals failed to reveal signs of a 
hypocellular marrow, ineffective hematopoiesis, or myelofibrosis. For 
rheumatologic causes, the presence of ANA and RF was investigated, 
and mildly elevated anti-dsDNA antibodies were discovered. Although 
anti-dsDNA antibodies measured by enzyme‐linked immunosorbent 
assay generally have a high specificity, low or equivocal titers may be 
induced by conditions other than SLE.4) Specifically, moderately posi-
tive titers indicate 72% specificity and equivocal titers indicate 65% 
specificity.5) As the titers never reached strongly positive levels and 
rather, decreased over time, we presumed that sepsis was responsible 
for the transient elevation of anti-dsDNA antibodies and rheumato-
logic factor. As for the presence of renal dysfunction seen in lupus ne-
phritis, both creatinine and cystatin C were measured to estimate the 
GFR, but the accuracy of creatinine-based estimated GFR was ques-
tionable due to the low BMI.6) Additionally, cystatin C is also known to 
be affected by positive RF;7) therefore, the exact renal function status of 
the patient could not be ascertained.
 Splenectomy was initially considered as a curative treatment as 
splenic sequestration was suspected due to the massive splenomegaly. 
Furthermore, it has been previously reported that splenectomy may 
have a curative effect in such cases.1) However, as the patient was criti-
cally ill, partial splenic embolism was performed instead to avoid the 
risks of surgery.8) Unfortunately, these measures failed to prevent the 
eventual death of the patient from septic shock.
 The role of family medicine is often described as ‘providing primary 
care from birth to the end of life.’ In the present case, we found our-
A B
Figure 1. (A, B) Splenic angiography images, taken on August 1, 2019, before (A) 
and after partial splenic embolization (B).
Figure 2. Abdominal computed tomography performed on August 4, 2019, at the 
first signs of septic shock. The image shows marked infarction of spleen with air 
bubbles and diffuse dilatation of small bowel loops without a transition point.
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selves in a dilemma regarding the optimal management of the patient. 
This case represented a diagnostic ‘gray zone,’ where the referral was 
rejected while no definitive treatment options could be decided upon 
even after consultations, due to the uncertain diagnosis. However, the 
condition was having a severely detrimental impact on the quality of 
life of the patient with no notable improvement over the long clinical 
course; therefore, the desire of the patient and his family for definitive 
treatment was considered before deciding the management plan. 
With consultations regarding medically unexplained physical symp-
toms becoming more common in recent times, similar dilemmas may 
occur in such ‘gray zone’ patients. Currently, although all subspecial-
ties put significant emphasis on disease management, less attention 
may be paid to the desires of the patients and their families. Family 
medicine may fill in the gaps here. As providers of comprehensive 
care, we can optimally incorporate the personal values of the patients 
and their families into the medical decisions, and thus help in decid-
ing the best course of action in similar situations. We hope that our ex-
perience in this case may give some insight into the management of 
future patients in the ‘gray zone.’
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